Suggestions

Du même auteur

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer

Archive ouverte | Bachelot, Thomas | CCSD

International audience. PURPOSE Everolimus, an oral inhibitor of the mammalian target of rapamycin, improves progression-free survival in combination with endocrine therapy (ET) in postmenopausal women with aromatas...

Concomitant medication, comorbidity and survival in patients with breast cancer

Archive ouverte | Dumas, Elise | CCSD

International audience. Abstract Between 30% and 70% of patients with breast cancer have pre-existing chronic conditions, and more than half are on long-term non-cancer medication at the time of diagnosis. Prelimina...

Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials

Archive ouverte | Rassy, Elie | CCSD

International audience

Chargement des enrichissements...